29 March 2019 - First EMA PRIME eligibility for Krystal Biotech.

Krystal Biotech announced today that the EMA has granted access to its PRIME (PRIority MEdicines) scheme for KB103 (bercolagene telserpavec), a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa. 

Krystal’s application was supported by clinical data to date from the ongoing GEM-1 Phase 1/2 study coupled with non-clinical data.

Read Krystal Biotech press release